The invention relates to extended release compositions and formulations comprising 6-thioguanine (6-TG), and methods for treating diseases or conditions responsive to 6-TG.

The application relates to compounds with activity against infectious viruses. Accordingly in one embodiment the invention provides a compound of the invention which is a compound of Formula I: (I) wherein: B is adenine guanine cytosine uracil thymine 7-deazaadenine 7-deazaguanine 7-deaza-8-azaguanine 7-deaza-8-azaadenine inosine nebularine nitropyrrole nitroindole 2-aminopurine 2-amino-6-chloropuriine 26-diaminopurine hypoxanthine pseudouridine pseudocytosine pseudoisocytosine 5-propynylcytosin...

In the present invention there is disclosed a pharmaceutical composition containing cyclopeptide cyclo-(Arg-Gly-Asp-D-Phe-NMe-Val) and/or a physiologically acceptable salt thereof and at least one chemotherapeutic agent and/or physiologically acceptable salts thereof being selected from the group consisting of a) alkylating agents selected from a group consisting of busulfan carboplatin carmustine cisplatin cyclophosphamide dacarbazine ifosfamide and lomustine b) antibiotics selected from a grou...

Disclosed is the use of a compound of formula 1, or a pharmaceutically acceptable salt or solvate thereof, or a mixture thereof, in an amount from 1 to 48 mg/m2 free base, together with an anti-cancer agent chosen from gemcitabine, 6-thioguanine, doxorubicin, cisplatin, irinotecan, and temozolomide, for treating cancer in a mammal. Also disclosed is the use of a compound of formula 1, or a pharmaceutically acceptable salt or solvate thereof, or a mixture thereof, in an amount from 2 to 96 mg fre...

Disclosed is a compound of the formula (I) wherein X2 is selected from O, NR and S

The application relates to compounds with activity against infectious viruses. Accordingly in one embodiment the invention provides a compound of the invention which is a compound of Formula I: (I) wherein: B is adenine guanine cytosine uracil thymine 7-deazaadenine 7-deazaguanine 7-deaza-8-azaguanine 7-deaza-8-azaadenine inosine nebularine nitropyrrole nitroindole 2-aminopurine 2-amino-6-chloropuriine 26-diaminopurine hypoxanthine pseudouridine pseudocytosine pseudoisocytosine 5-propynylcytosin...

The application relates to compounds with activity against infectious viruses. Accordingly in one embodiment the invention provides a compound of the invention which is a compound of Formula I: (I) wherein: B is adenine guanine cytosine uracil thymine 7-deazaadenine 7-deazaguanine 7-deaza-8-azaguanine 7-deaza-8-azaadenine inosine nebularine nitropyrrole nitroindole 2-aminopurine 2-amino-6-chloropuriine 26-diaminopurine hypoxanthine pseudouridine pseudo-cytosine pseudoisocytosine 5-propynylcytosi...

This invention concerns conjugates of transferrin albumin and polyethylene glycol consisting of native or thiolated transferrin or albumin or of polyethylene glycol (MW between approx. 5000 and 200 000) with at least one HS- HO- or H2N group and cytostatic compounds derived through maleinimide or N-hydroxysuccinimide ester-compounds such as doxorubicene daunorubicene epirubicene idarubicene mitoxandrone chlorambucil melphalan 5-fluorouracyl 5'-desoxy-5-fluorouridene thioguanine methotrexate pacl...

The present invention provides for a topical composition that includes a topical carrier and an adenosine deaminase inhibitor. Suitable specific adenosine deaminase inhibitors include, e.g., deoxycoformycin (dCF), deoxyadenosine (dAdo), cladrabine (CdA), fludarabine (F-Ara-A), cytrabine (Ara-C), and thioguanine. The present invention also provides for a method to treat lymphocyte mediated skin diseases and to alleviate symptoms associated with such skin diseases. The method includes topically ad...

The invention relates to compositions containing nanoparticles and to uses o f said compositions for encapsulating therapeutically active substances in cel ls by means of nanoparticles with a particular coating. The particles are chemically formed in such a way as to enable a high intracellular absorption into the cells. The encapsulation requires no direct binding between nanoparticles and the therapeutically active substance. The encapsulation enables an increased efficiency of the substance w...